AMH and ovarian reserve: what the result can and cannot predict
AMH helps assess ovarian reserve and the expected response to stimulation, but it does not provide a personal yes-or-no answer about becoming pregnant. A low result matters for planning; it should not be turned into a verdict on its own. Before choosing IVF in Turkey, it is more useful to understand how the result changes your particular plan than to compare your number with someone else’s online story.
What ovarian reserve describes
Ovarian reserve concerns the quantity of eggs remaining. AMH is an indirect marker; the blood test does not count every egg or test each egg’s quality. ASRM distinguishes quantity from quality and explains that AMH and antral follicle count predict response to stimulation better than they predict the birth of a baby.
In practice, that means two separate conversations. One concerns the expected egg yield with the proposed approach. The other concerns the wider fertility picture, including age and other factors. If a clinic answers both questions with the AMH number alone, ask for the conclusions and their limitations to be separated.
Send the complete laboratory report
Include the date, measurement units and laboratory name rather than typing the number into a message. State your age and the medicines used when the sample was taken. ASRM notes that hormonal contraception can affect AMH levels; this is a reason for clinical interpretation, not for stopping treatment yourself.
If earlier results and an ultrasound antral follicle count are available, arrange them chronologically. A difference between two tests does not automatically establish a laboratory error. The clinician can explain whether they are comparable and whether repeating a test would change the decision. Testing should answer a clinical question, rather than simply aim to produce a more reassuring number.
What a low result changes now
ASRM advises that an extremely low AMH result alone should not be used to refuse IVF. That is not a promise of a successful outcome. The consultation still needs to address the likely response, possible limitations and which findings during the next stage would lead to a change of plan.
If you have already had treatment, the actual cycle record may be useful: the follicles observed, eggs collected and what happened afterwards. “A failed attempt” does not identify the stage at which the difficulty occurred. These records help prevent a repeat consultation from being reduced to another AMH measurement when earlier treatment already provides relevant information.
Can AMH choose the clinic or travel dates?
A single result cannot establish which clinic is best for you or set a precise timetable. Compare the explanations instead: is there a proposed next step, a reason for that approach and a clear account of what is still uncertain? Be cautious about an unexplained promise to “increase your reserve” and thereby guarantee pregnancy. Ask which outcome is actually being claimed and what evidence supports it.
Before payment, obtain separate medical and practical answers: what the clinician proposes to consider, and which visits that stage needs. Confirm that your individual circumstances can be accepted and which eligibility documents are required. An overseas clinical guideline does not establish the rules for access to treatment in Turkey.
Start with the results you already have and a brief history of fertility investigations and treatment. The purpose is an understandable interpretation of AMH in context, with room for an individual decision, rather than replacing an alarming laboratory result with a new unsupported promise.
Sources
Medicina Turkey patient information. General guidance; individual medical decisions should be discussed with the treating clinician.